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Abstract: HIV-1 integrase (IN) inhibitors represent a new class of highly effective anti-AIDS
therapeutics. Current FDA-approved IN strand transfer inhibitors (INSTIs) share a common
mechanism of action that involves chelation of catalytic divalent metal ions. However, the emergence
of IN mutants having reduced sensitivity to these inhibitors underlies efforts to derive agents that
antagonize IN function by alternate mechanisms. Integrase along with the 96-residue multifunctional
accessory protein, viral protein R (Vpr), are both components of the HIV-1 pre-integration complex
(PIC). Coordinated interactions within the PIC are important for viral replication. Herein, we report
a 7-mer peptide based on the shortened Vpr (69–75) sequence containing a biotin group and a
photo-reactive benzoylphenylalanyl residue, and which exhibits low micromolar IN inhibitory
potency. Photo-crosslinking experiments have indicated that the peptide directly binds IN.
The peptide does not interfere with IN-DNA interactions or induce higher-order, aberrant IN
multimerization, suggesting a mode of action for the peptide that is distinct from clinically used
INSTIs and developmental allosteric IN inhibitors. This compact Vpr-derived peptide may serve as a
valuable pharmacological tool to identify a potential new pharmacologic site.
Keywords: HIV-1 integrase; viral protein R; photoaffinity probe; inhibitor
1. Introduction
HIV-1 integrase (IN) is a virally encoded polynucleotidyl transferase that inserts
reverse-transcribed viral cDNA into the host genome using two sequential reactions, cleavage of the
3′-dinucleotides from viral DNA, referred to as 3′-processing (3′-P), and insertion of the processed ends
of viral DNA into the host genome, termed strand transfer (ST) [1]. Integrase strand transfer inhibitors
(INSTIs) are the newest class of AIDS therapeutic, with three FDA-approved agents now being on
the market (raltegravir (RAL, October 2007) [2], elvitegravir (EVG, August 2012) [3] and dolutegravir
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(DTG, August 2013) [4]). Drug resistance can be an unwanted side effect of long-term therapy using
anti-AIDS drugs and the most recently introduced INSTIs do not present an exception [5,6]. Therefore,
efforts continue to develop new inhibitors that are not affected by the extant INSTI-resistant forms
of IN.
Binding of INSTIs to the enzyme catalytic site occurs in the cytoplasm, where IN exists in
multimeric form as part of a pre-integration complex (PIC), which contains other viral proteins that
include reverse transcriptase (RT), matrix protein (MA) and viral protein R (Vpr). Multiple host
cofactors are also involved in the formation of the PIC, such as lens epithelium-derived growth factor
(LEDGF)/transcriptional coactivator p75. Full proviral DNA integration requires entry of the PIC into
the nucleus and proper chromosomal insertion. The catalytic activity and nuclear localization of IN
are facilitated by cellular and viral proteins including Vpr and LEDGF [7,8]. Synthetic peptides that
mimic structural elements employed by these cofactors to carry out their roles in viral replication may
provide new classes of inhibitors that are less affected by resistance mutants arising from catalytic
site-binding INSTIs [9–11]. Indeed, peptides based on sequences of the LEDGF integrase-binding
domain (IBD) have been shown to inhibit catalytic function, in part by shifting the equilibrium of IN
oligomerization [12]. As Vpr exerts its complex and not completely understood role in the pathogensis
of HIV-1 in non-dividing cells, it potentially affords a new and alternate non-catalytic target for
therapeutic exploration [13–18].
Vpr is a 96-residue protein having flexible N- and C-termini. These bracket three internal,
well-defined α-helices (I–III; residues 17–33, 38–50 and 56–77, respectively), which are folded about
a hydrophobic core (Figure 1A) [19]. An early report showed that C-terminal residues [Vpr (52–96)]
are responsible for binding of IN to viral DNA, with evidence suggesting that residues 88–96 are
particularly important [20,21]. A screen of peptides sharing 11-amino acid overlaps and covering the
full Vpr protein, identified Vpr (61–75) (IRILQQLLFIHRIG) in α-helix III as being able to inhibit most
potently both the 3′-P and ST in vitro (Figure 1B) [22]. Recent work examining the ability of peptides
derived from HIV-1 gene products to inhibit IN has identified the Vpr (64–69) sequence “LQQLLF”
as being shared by pooled 15-mer Vpr-derived peptides. These peptides showed good ST-inhibitory
potencies (IC50 = 68 µM) [23]. Their sequence occupies the central region of the Vpr C-terminal α-helix.
Extending the sequence to cover more of the α-helix by adding the Vpr (69–75) residues (IHFRIG)
was shown to increase inhibitory potency [23]. In further work, these authors examined the effects on
IN inhibitory potencies incurred by employing ring-closing metathesis “stapling” to stabilize α-helix
conformations of the Vpr (58–75)-derived sequence, “EAIIRILQQLL FIHFRIG” [24]. These structural
modifications left unchanged the C-terminal “FIHFRIG”-containing region.
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Figure 1. NMR solution structure of Vpr (1–96) (PDB accession code: 1M8L [19]). (A) Full-length
structure showing helices; (B) Closeup of α-helix III showing residues “FIHFRIG” (69–75) overlain on
a ribbon depiction.
The assays described above were performed using purified IN in the absence of other proteins
that comprise essential components of the PIC. There is no evidence that Vpr binds directly to IN
within a cellular context [18]. In light of this, the ability of Vpr-derived peptides to inhibit IN in in vitro
assays may reflect binding to sites on IN that may be unrelated to the other functions of Vpr in vivo.
Our current work was undertaken to identify minimal Vpr-derived sequences that retain micromolar
IN inhibitory potencies in in vitro assays and to introduce photoaffinity crosslinking functionality into
the best peptides to provide pharmacological probes that might be useful in delineating regions of IN
that are important for peptide binding [25].
2. Results and Discussion
2.1. Development of a Core Vpr-Derived IN Inhibitory Peptide
We began our work by exploring the Vpr (69–75) peptide “FIHGRIG”. This sequence was of
interest, not only because it had been shown to increase inhibitory potency when added to shorter Vpr
(65–69) derive peptides from the Vpr α-helix III, but also because it is contained within a Vpr (65–79)
peptide (QQLLFIHFRIGCQHS), which had been report d to exhibit good IN ST-inhibitory potency
(IC50 = 14 µM) [22]. We found that the shortened sequenc can exhibit low microm lar inhibitory
potency in in vitro IN assays, with greater efficacy against the ST reaction relative to 3′-P reac ions.
The harge-state of th peptide terminal groups affected inhibitory potencies. Peptid s having both
termi i free (1a; 3′-P IC50 = 18± 1 µM; ST IC50 = .3± 0.3 µM) or the C-terminus as a carboxamide and
the amino termi us as its acetamide (1c; 3′-P IC50 = 24± 3 µM; ST IC50 = 4.7± 0.3 µM) were marginally
more potent than the carb xamide peptide having a fre amino terminus (1b; 3′-P IC50 = 32 ± 6 µM;
ST IC50 = 7.3 ± 0.8 µM) (Table 1).
Next, to determine the relative contribution of each residue to overall inhibitory potency,
we performed a sequential alanine scan on the peptides 1a–c. This yielded three series of congeners
2a–c through 8a–c. Alanine substitution at all positions decreased IN inhibitory potencies relative
to the parent peptides. Peptides containing a free amino terminus with a C-terminal carboxamide
showed the lowest potency for a given alanine substitution (peptides 2b–8b) (Table 1). The greatest
loss of potencies occurred by substitution of the Arg (Vpr73), Phe (Vpr72) and Ile (Vpr70) residues.
The Arg and Ile residues are of note, as they occupy the i and i + 4 positions on the same side of α-helix
III that faces outward from the hydrophobic core comprised of α-helices I and II (Figure 1B). This could
potentially make them accessible for interactions with other proteins. Interestingly, while replacing
Molecules 2018, 23, 1858 4 of 15
the amino-terminal Phe (Vpr69) residue with hydrophobic residues was generally well tolerated,
replacement with Glu abrogated both 3′-P and ST-inhibitory potencies (IC50 values greater than
111 µM; data not shown). This may reflect formation of an intramolecular salt bridge arising between
the anionic Glu side chain and the guanidinium moiety of the Arg (Vpr73) residue, which could
interfere with the ability of this latter residue to engage in protein-protein interactions (PPIs) (refer to
Figure 1B for side chain proximity).
Table 1. Structures of peptides and 3′-P and ST-inhibitory potencies in in vitro IN assays.
No. SEQUENCE i 3’-P IC50 (µM) ST IC50 (µM)
1a FIHFRIG 17.6 ± 1.2 1.3 ± 0.3
1b FIHFRIG-amide 31.5 ± 6 7.3 ± 0.8
1c Ac-FIHFRIG-amide 23.5 ± 3 4.7 ± 0.3
2a FIHFRIA >111 34.7 ± 2.3
2b FIHFRIA-amide >111 60.6 ± 8
2c Ac-FIHFRIA-amide 74.5 ± 7 30.4 ± 0.7
3a FIHFRAG 66.5 ± 7 22.4 ± 1.7
3b FIHFRAG-amide > 111 >111
3c Ac-FIHFRAG-amide 208 ± 12 28 ± 4
4a FIHFAIG >111 >111
4b FIHFAIG-amide >111 >111
4c Ac-FIHFAIG-amide >333 81 ± 9
5a FIHARIG >111 46.6 ± 6.5
5b FIHARIG-amide >111 >111
5c Ac-FIHARIG-amide >333 117 ± 10
6a FIAFRIG 17.4 ± 2.0 6.7 ± 1.0
6b FIAFRIG-amide 95.4 ± 5 35.0 ± 3.2
6c Ac-FIAFRIG-amide 94 ± 13 3.5 ± 0.3
7a FAHFRIG >111 73.5 ± 6.0
7b FAHFRIG-amide >111 >111
7c Ac-FAHFRIG-amide >333 127 ± 14
8a AIHFRIG 86.3 ± 5.0 22.7 ± 1.4
8b AIHFRIG-amide >111 >111
8c Ac-AIHFRIG-amide >333 46 ± 8
9a FIHFRBG 20 ± 3 4.3 ± 1.3
10a FIHFBIG >333 48 ± 8
11a FIHBRIG 34 ± 6 4.2 ± 0.7
12a FIBFRIG 6.5 ± 0.9 2.2 ± 0.6
13a FBHFRIG 37 ± 5 20 ± 3
14a BIHFRIG 7.2 ± 1.2 2.1 ± 0.3
15 Biotin-linker-BIHFRIG 32 ± 7 2.3 ± 0.3
i “A” represents “Ala, Alanine”, “B” represents “Bpa, benzoylphenylalanine”.
2.2. Peptide 1a Does Not Interfere with IN–DNA Binding or Induce Aberrant IN Multimerization
To further our understanding of the mode of IN inhibition by Vpr-derived peptides, we evaluated
the effect of 1a on IN–DNA complex formation using fluorescence anisotropy. The results showed that
preincubation of IN with 1a did not block the IN–DNA interactions, but rather promoted IN–DNA
complex formation (Figure 2A), as demonstrated by the increased fluorescence polarization upon
treatment with increasing concentrations of 1a. Consistent with this finding, the C-terminal Vpr
peptides, including Vpr (65–79), have been shown to interact with IN [20]. We also investigated the
binding of 1a to the DNA substrate alone (Figure 2B) and found no detectable binding of 1a to DNA at
concentrations up to 37 µM, which were sufficient for inhibition of IN by 1a [IC50 (3′-P) 17.6 µM, IC50
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(ST) 1.3 µM, Table 1]. The increase in fluorescence at high concentrations of 1a, [111 µM and 333 µM
(Figure 2)], can potentially be associated with multimerization of 1a [26]. Indeed, the Vpr Helix III
motif residues within 1a, (69–71 and 74) were shown to contribute to the Vpr dimerization interfaces
via either parallel or antiparallel modes [26]. Because the increase of fluorescence polarization, which is
indicative of 1a–DNA binding, was only observed at concentrations of 1a above 37 µM (Figure 2B),
while this concentration did not disrupt IN–DNA complex formation, it is likely that 1a multimers
are not the IN-inhibiting species. These fluorescence experiments show that 1a does not disrupt
IN–DNA complexes and that it does not bind to DNA alone at concentrations relevant to IN inhibition.
This suggests that 1a exerts its inhibitory activity by binding to IN or IN–DNA complexes.
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Figure 2. The binding properties of peptide 1a to IN–DNA complex and DNA alone evaluated over
time by fluorescence anisotropy or in the presence of IN (400 nM) preincubated with 1a at the indicated
concentrations (A) or in the absence of IN (B). Different concentrations of peptide 1a are color-coded:
0 µM in black; 12 µM in red; 37 µM in pink; 111 µM in gray; 333 µM in blue.
Recently, allosteric HIV-1 IN inhibitors (ALLINIs) have been identified, which induce higher-order,
aberrant IN multimerization in vitro and in virions, and inhibit proper virus particle maturation [27–35].
Using a homogeneous time-resolved fluorescence resonance energy transfer (HTRF) assay [36],
we found that unlike a representative ALLINI (BI-1001), 1a did not induce higher-order IN
multimerization, suggesting an allosteric IN inhibition mechanism that differs from that used by
ALLINIs (Figure 3) [27].
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2.3. Development of a Vpr Peptide-Based Photoprobe
How Vpr-derived peptides interact with IN to inhibit its catalytic function is not known. However,
identifying the region of IN engaged by the Vpr (69–75) peptides may clarify the processes involved.
This could serve as a first step in developing novel allosteric inhibitors with a distinct mechanism
from small molecule catalytic site-directed IN inhibitors. Photoaffinity crosslinking can be a highly
useful means to identify ligand-binding regions. The benzophenone moiety is stable in ambient light,
yet at wavelengths of light in the region 350–360 nm, photo-activation can occur, which can lead to
covalent modification of C–H bonds, even under aqueous conditions [37–39]. We have previously
incorporated benzophenones into coumarin-based IN inhibitors [40] and used this approach to identify
their binding sites on HIV-1 IN through photo-crosslinking [41]. We have also applied this photophore
to 2,4-dioxobutanoic acid-based IN inhibitors [42,43]. The benzoylphenylalanine (Bpa) variant of
phenylalanine can be used to render peptides photo-reactive for the identification peptide-protein
interactions [44].
It was unclear whether introducing a Bpa residue into the parent peptide 1a could be done
in a fashion that would not disrupt its binding to IN. Accordingly, beginning with the Vpr74 Ile
residue, we conducted a positional scan that sequentially replaced each residue of the peptide with Bpa
(peptides 9a–14a). Substitution was notably well tolerated at nearly all positions examined. Relative
to the parent peptide 1a, replacement of the Vpr74 Ile residue with Bpa did not diminish inhibitory
potency [1a, 3′-P IC50 = 18 µM, ST IC50 = 1 µM as compared to 9a, 3′-P IC50 = 20 µM, ST IC50 = 4 µM
(Table 1)]. Consistent with the results of the alanine scan, replacement of the Vpr73 Arg with Bpa gave
the most dramatic loss of inhibitory potency as compared with substitutions of other Vpr residues
(10a, 3′-P IC50 > 300 µM, ST IC50 ' 50 µM). This further supports the hypothesis that this Arg residue
may play a critical role in binding to IN. The second-most adverse impact on inhibitory potency
occurred by substitution of the Vpr70 Ile residue (13a, 3′-P IC50 = 37 ± 5 µM, ST IC50 = 20 ± 3 µM).
This also parallels results of the alanine scan, where substitution at this position had the next-to greatest
effect (peptide 7a). As pointed out above, the Vpr70 Ile and Vpr73 Arg residues occupy relative i
and i + 4 positions within the α-helix III, which would place them on the same outward-facing side
(Figure 1B). The best inhibitory potency was observed by replacing the Vpr69 Phe residue with Bpa
[14a, 3′-P IC50 = 7.2 ± 1.2 µM, ST IC50 = 2.1 ± 0.3 µM) (Table 1)]. These values are approximately
10-fold lower than what was observed by replacing Phe with Ala (peptide 8a).
Based on the above results, we selected peptide 14a as a platform for further photoprobe
construction. Because low crosslinking efficiency and high background noise can be problematic
barriers to effective applications of photoaffinity ligands, biotin tags are often included as parts of the
photoaffinity ligands to allow visualization and purification of covalent adducts [45–47]. Accordingly,
we incorporated a biotin moiety by tethering it from the amino terminus using a hydrophilic linker
and we found that inhibitory potency was retained [15, 3’-P IC50 = 32 ± 7 µM, ST IC50 = 2.3 ± 0.3 µM
(Figure 4A)].
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Figure 4. Integrase crosslinking studies. (A) Structure of photoprobe 15 showing inhibitory potencies in
an in vitro IN assay. (B) Interaction of 15 with IN as evaluated by Western blotting after UV crosslinking
(254 nM) and separation on Invitrogen Novex 4–20% Tris-Glycine gels (Invitrogen™ Novex™ SeeBlue™
Plus2 prestained protein standard is included in the outmost left lane): Lane 1, HIV-1 IN only (60 min
UV); Lane 2, Peptide 15 only (60 min UV); Lane 3, IN and peptide 15 (60 min UV); Lane 4, 30 min UV;
Lane 5, 15 min UV; Lane 6, 5 min UV; Lane 7, HIV-1 IN only; Lane 8, Peptide 15 only; Lane 9, IN and
15. Gel stained with rabbit anti-IN CTD polyclonal (260–280)/anti-rabbit Licor, 680 nm (center, red),
streptavidine-AlexaFluor 750 nm (right, green), merged image (left, merged). Molecular size markers
are indicated at left (kDa).
We incubated 15 with IN and subjected the mixture to UV irradiation followed by SDS-PAGE
separation of protein products. The presence of IN was detected by Western blotting using an anti-IN
C-terminal domain (CTD) polyclonal antibody (Figure 4B). The presence of 15 was revealed on the
same Western blot membrane using streptavidin-coupled AlexaFluor 750. To facilitate the detection of
crosslinking products by Western blot, relatively high concentrations of 15 (111 µM) and IN (3.2 µM)
were used. The biotin-bound entities were visualized as green on the blot, whereas IN and some
of the proteins from the prestained standard were colored red (Figure 4B). Upon UV irradiation of
the preincubated mixture containing 15 and IN, a product was formed that contained biotin label
and comigrated with IN on the gel (Figure 4B, Lanes 3–6). This indicated the presence of covalent
adducts of 15 with IN. Such adducts are lacking when IN was irradiated in absence of 15 (Figure 4B,
Lane 1) or when the mixture was not UV treated (Figure 4B, lane 9). Additionally, the crosslinked
product (Figure 4B, Lanes 3–6) migrated at the same rate as the non-crosslinked IN (Figure 4B, Lane 7).
This suggests that a monomeric IN subunit (molecular weight of 34.5 kDa) forms a single crosslink to
15 (molecular weight of 1449 Da), which indicates close to a 1:1 stoichiometry for 15–IN interaction.
In addition to the 15–IN product, a high molecular weight product was formed, which also contained
the biotin label (Figure 4B, Lanes 2–6, top bands). This product formed in the absence of IN (Figure 4B,
Lane 2) and its accumulation was time-dependent (Figure 4B, Lanes 3–6). Formation of biotinylated
high molecular weight product could be explained by polymerization of 15 upon irradiation.
Potential multimerization of the Vpr-derived peptides would likely facilitate such polymerization.
This corroborates the results of fluorescence anisotropy experiments, which demonstrated the binding
of 1a to DNA at high concentrations [111 µM and 333 µM (Figure 2)]. Despite polymerization of
15, no reaction of polymeric product with IN could be detected as shown by UV irradiation of 15 in
absence and in presence of IN (Figure 4B, Lanes 2 and 3, respectively). This further suggests that
potential multimers of Vpr-derived peptide do not bind or inhibit IN. Although the multimerization of
Vpr-derived peptide inhibitors of IN could not be entirely ruled out, our anisotropy and crosslinking
results indicate that it is monomeric peptides (i.e., 1a or 15) that are responsible for IN inhibition.
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3. Materials and Methods
3.1. General Synthetic
Preparative high-performance liquid chromatography (HPLC) was conducted using a Waters
Prep LC4000 system (Milford, MA, USA) having photodiode array detection and a Phenomenex
C18 column (00G-4436-P0-AX, 250 mm × 21.2 mm, 10 µm particle size, 110 Å pore Phenomenex,
Torrance, CA, USA) at a flow rate of 10 mL/min. Binary solvent systems consisting of A = 0.1%
aqueous trifluoroacetic acid (TFA) and B = 0.1% TFA in acetonitrile were employed with gradients,
as indicated. Products were obtained as amorphous solids following lyophilization. Electrospray
ionization-mass spectra (ESI-MS) and the purity of final peptides were determined with an Agilent
LC/MS system (Santa Clara, CA, USA). Matrix-assisted laser desorption/ionization (MALDI) mass
spectra were acquired on a Shimadzu Biotech Axima-CFR time-of-flight instrument (Columbia, MD,
USA) using a-cyano-4-hydroxycinnamic acid as matrix. High-resolution mass spectra (HRMS) were
acquired by LC/MS-ESI using an LTQ-Orbitrap-XL (ThermoFisher Scientific, Grand Island, NY, USA)
at 30 K resolution.
3.2. Peptide Synthesis
Amino acid reagents, Fmoc-Gly-OH, Fmoc-Phe-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH
and Fmoc-Ala-OH were obtained from NOVA Biochem (MilliporeSigma, Burlington, MA,
USA). Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-4-benzoyl-L-phenylalanine [Fmoc-L-Bpa-OH],
D-(+)-biotin and were obtained from Chem-Impex International, Inc (Wood Dale, IL,
USA). The linker reagent for appending biotin to the amino terminus in peptide 15
[1-(9H-fluoren-9-yl)-3,14-dioxo-2,7,10-trioxa-4,13-diazaheptadecan-17-oic acid] was prepared from
succinic anhydride and 2,2′-(ethylenedioxy)bis(ethylamine) according to literature procedures [48].
Fmoc-Gly-Wang resin and Rink amide MBHA (4-methylbenzhydrylamine) resin were obtained
from Novabiochem.
Peptides were synthesized using standard Fmoc solid-phase peptide synthesis (SPPS)
protocols using active ester coupling methodology in N-methylpyrrolidinone (NMP) using
a CEM Liberty Microwave Peptide Synthesizer (CEM Corporation, Matthews, NC, USA).
In summary, the protected amino acids or acid (5.0 eq. based on resin loading, 0.2 M in NMP),
O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) (5.0 eq., 0.45 M in
NMP) and N,N-diisopropylethylamine (DIEA) (5.0 eq., 2 M in NMP) were coupled using microwave
irradiation (75 ◦C, 5 min, double couple). Fmoc deprotection was accomplished using 20% piperidine in
NMP (with 0.1 M 1-hydroxybenzotriazole hydrate (HOBt). Where appropriate, N-terminal acetylation
was achieved by manual coupling using 1-acetylimidazole (10% w/v in DMF). Final resins were
washed sequentially with NMP, MeOH, CH2Cl2, and Et2O and dried under vacuum (overnight).
Peptides were cleaved from the resin by treatment with a cocktail solution of TFA: triisopropylsilane
(TIS): H2O (95: 2.5: 2.5; 5 mL, 4 h). The resin was removed by filtration and the peptide was precipitated
in cold Et2O and the precipitate was centrifuged and washed with Et2O. The resulting white solid was
dissolved in 50% aqueous acetonitrile (4 mL) and purified by reverse phase preparative HPLC using
linear gradients as indicated below. Final peptides were characterized as indicated in the General
Synthetic section using ESI-MS, MALDI-MS or HRMS. Data are presented below:
Peptide 1a. Linear gradient of 15% B to 30% B over 30 min; retention time = 25.9 min. ESI-MS calcd for
C44H65N12O8 [MH+], 889.5; found, 889.3.
Peptide 1b. Linear gradient of 15% B to 30% B over 30 min; retention time = 22.9 min. ESI-MS calcd for
C44H66N13O7 [MH+], 888.5; found, 888.4.
Peptide 1c. Linear gradient of 20% B to 40% B over 30 min; retention time = 22.4 min. ESI-MS calcd for
C46H68N13O8 [MH+], 930.5; found, 930.4.
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Peptide 2a. Linear gradient of 15% B to 30% B over 30 min; retention time = 27.0 min. MALDI-MS calcd
for C45H67N12O8 [MH+], 903.5; found, 903.7.
Peptide 2b. Linear gradient of 15% B to 30% B over 30 min; retention time = 24.2 min. ESI-MS calcd for
C45H68N13O7 [MH+], 902.5; found, 902.4.
Peptide 2c. Linear gradient of 20% B to 40% B over 30 min; retention time = 22.3 min. ESI-MS calcd for
C47H70N13O8 [MH+], 944.5; found, 944.4.
Peptide 3a. Linear gradient of 15% B to 25% B over 30 min; retention time = 20.7 min. ESI-MS calcd for
C41H59N12O8 [MH+], 847.5; found, 847.4.
Peptide 3b. Linear gradient of 15% B to 25% B over 30 min; retention time = 18.2 min. MALDI-MS calcd
for C41H60N13O7 [MH+], 846.5; found, 846.3.
Peptide 3c. Linear gradient of 20% B to 40% B over 30 min; retention time = 17.1 min. ESI-MS calcd for
C43H62N13O8 [MH+], 888.5; found, 888.4.
Peptide 4a. Linear gradient of 15% B to 40% B over 30 min; retention time = 23.7 min. MALDI-MS calcd
for C41H58N9O8 [MH+], 804.4; found, 804.6.
Peptide 4b. Linear gradient of 15% B to 25% B over 30 min; retention time = 28.5 min. MALDI-MS calcd
for C41H59N10O7 [MH+], 803.5; found, 803.7.
Peptide 4c. Linear gradient of 20% B to 40% B over 30 min; retention time = 28.1 min. ESI-MS calcd for
C43H61N10O8 [MH+], 845.5; found, 845.4.
Peptide 5a. Linear gradient of 10% B to 20% B over 30 min; retention time = 27.9 min. MALDI-MS calcd
for C38H61N12O8 [MH+], 813.5; found, 813.5.
Peptide 5b. Linear gradient of 10% B to 20% B over 30 min; retention time = 23.4 min. MALDI-MS calcd
for C38H62N13O7 [MH+], 812.5; found, 812.5.
Peptide 5c. Linear gradient of 20% B to 30% B over 30 min; retention time = 14.4 min. ESI-MS calcd for
C40H64N13O8 [MH+], 854.5; found, 854.4.
Peptide 6a. Linear gradient of 15% B to 40% B over 30 min; retention time = 23.9 min. MALDI-MS calcd
for C41H63N10O8 [MH+], 823.5; found, 823.7.
Peptide 6b. Linear gradient of 15% B to 30% B over 30 min; retention time = 29.1 min. ESI-MS calcd for
C41H64N11O7 [MH+], 822.5; found, 822.3.
Peptide 6c. Linear gradient of 20% B to 40% B over 30 min; retention time = 28.8 min. ESI-MS calcd for
C43H66N11O8 [MH+], 864.5; found, 864.4.
Peptide 7a. Linear gradient of 15% B to 25% B over 30 min; retention time = 25.9 min. MALDI-MS calcd
for C41H59N12O8 [MH+], 847.5; found, 847.9.
Peptide 7b. Linear gradient of 15% B to 25% B over 30 min; retention time = 21.9 min. ESI-MS calcd for
C41H60N13O7 [MH+], 846.5; found, 846.4.
Peptide 7c. Linear gradient of 20% B to 40% B over 30 min; retention time = 18.4 min. ESI-MS calcd for
C43H62N13O8 [MH+], 888.5; found, 888.4.
Peptide 8a. Linear gradient of 15% B to 25% B over 30 min; retention time = 25.9 min. ESI-MS calcd for
C38H61N12O8 [MH+], 813.5; found, 813.3.
Peptide 8b. Linear gradient of 15% B to 25% B over 30 min; retention time = 21.4 min. ESI-MS calcd for
C38H62N13O7 [MH+], 812.5; found, 812.8.
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Peptide 8c. Linear gradient of 20% B to 30% B over 30 min; retention time = 17.9 min. ESI-MS calcd for
C40H64N13O8 [MH+], 854.5; found, 854.4.
Peptide 9a. Linear gradient of 15% B to 50% B over 30 min; retention time = 22.0 min. ESI-MS m/z:
1027.3 (MH+). HRMS calcd for C54H67N12O9 [MH+], 1027.5148; found, 1027.5161.
Peptide 10a. Linear gradient of 20% B to 50% B over 30 min; retention time = 24.0 min. ESI-MS m/z:
984.4 (MH+). HRMS calcd for C54H66N9O9 [MH+], 984.4978; found, 984.4969.
Peptide 11a. Linear gradient of 20% B to 35% B over 30 min; retention time = 24.9 min. ESI-MS m/z:
993.4 (MH+). HRMS calcd for C51H69N12O9 [MH+], 993.5305; found, 993.5310.
Peptide 12a. Linear gradient of 20% B to 50% B over 30 min; retention time = 24.1 min. ESI-MS m/z:
1003.3 (MH+). HRMS calcd for C54H71N10O9 [MH+], 1003.5400; found, 1003.5402.
Peptide 13a. Linear gradient of 20% B to 40% B over 30 min; retention time = 21.0 min. ESI-MS m/z:
1027.3 (MH+). HRMS calcd for C54H67N12O9 [MH+], 1027.5148; found, 1027.5168.
Peptide 14a. Linear gradient of 20% B to 50% B over 30 min; retention time = 17.6 min. ESI-MS m/z:
993.4 (MH+). HRMS calcd for C51H69N12O9 [MH+], 993.5305; found, 993.5315.
Peptide 15. Linear gradient of 20% B to 45% B over 30 min; retention time = 25.7 min. ESI-MS m/z:
1449.6 (MH+). HRMS calcd for C71H101N18O15S [MH+], 1449.7348; found, 1449.7358.
3.3. In Vitro Integrase Catalytic Assays
IN reactions were performed as previously described [49]. The reactions were carried by
incubating a mixture of 20 nM [γ-32P]-labeled DNA and 400 nM IN in a buffer containing 50 mM
morpholinepropanesulfonic acid (pH 7.2), 7.5 mM MgCl2, and 14 mM 2-mercaptoethanol in the
absence or presence of peptide inhibitors in DMSO (vehicle) at eight three-fold dilutions ranging from
111 µM to 50 nM. Reactions were performed at 37 ◦C (2 h) and quenched by the addition of an equal
volume of loading buffer (formamide containing 1% sodium dodecyl sulfate, 0.25% bromophenol
blue, and xylene cyanol). Reaction products were separated in 16% polyacrylamide denaturing
sequencing gels. Dried gels were visualized using a Typhoon 8600 instrument (GE Healthcare, Chicago,
IL, USA). Densitometric analyses were performed using ImageQuant 5.1 software (GE Healthcare,
Chicago, IL, USA). Data analyses (linear regression, 50% inhibitory concentration [IC50] determination,
standard deviation [SD]) were performed from at least 3 independent determinations using Prism
5.0c software from GraphPad (La Jolla, CA, USA). To assay 3′-P inhibitory potency, reactions were
carried out with [γ-32P]-labeled full-length oligonucleotide 21T (GTGTGGAAAATCTCTAGCAGT)
annealed to the complementary oligonucleotide 21B (ACTGCTAGAGATTTTCCACAC). Formation
of the shorter processed 19T products was monitored and quantified to assess enzyme performance
and inhibitor potency. The ST reactions were carried out with the [γ-32P]-labeled pre-cleaved
oligonucleotide 19T (GTGTGGAAAATCTCTAGCA) annealed to the complementary oligonucleotide
21B (ACTGCTAGAGATTTTCCACAC) and formation of integration products (longer and slower
migrating than the starting 19T substrate) was monitored to assess enzyme performance and
inhibitor potency.
3.4. Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF)-Based Protein-Protein
Interaction Assays
WT HIV-1 IN recombinant proteins with His or FLAG tags [50] were expressed in Escherichia
coli and purified as described previously [27]. The His6–tagged IN construct was purified by loading
the cell lysate onto a Nickel-Sepharose column (GE Healthcare, Chicago, IL, USA) and eluting bound
integrase with an imidazole gradient in a 50 mM HEPES (pH 7.5) buffer containing 1 M NaCl,
7.5 mM CHAPS, 2 mM beta-mercaptoethanol. Peak fractions were pooled, diluted and loaded onto
a heparin column (GE Healthcare), and integrase was eluted with an increasing NaCl gradient
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in a 50 mM HEPES (pH 7.5) buffer containing 7.5 mM CHAPS and 2 mM beta-mercaptoethanol.
The FLAG-tagged IN construct was purified by loading the ammonium sulfate precipitate of cell
lysate onto a phenyl-Sepharose column (GE Healthcare) and eluting bound integrase with a decreasing
ammonium sulfate gradient in a 50 mM HEPES (pH 7.5) buffer containing 200 mM NaCl, 7.5 mM
CHAPS, 2 mM beta-mercaptoethanol. Peak fractions were pooled and loaded onto a heparin column
(GE Healthcare), and integrase was eluted with an increasing NaCl gradient in a 50 mM HEPES
(pH 7.5) buffer containing 7.5 mM CHAPS and 2 mM beta-mercaptoethanol. The HTRF-based IN
multimerization assays were performed by mixing 6 × His-tagged and FLAG-tagged INs (each at
10 nM final concentration) in a 25 mM Tris (pH 7.4) buffer containing 150 mM NaCl, 2 mM MgCl2,
0.1% Nonidet P-40, 1 mg/mL BSA. Test compounds were then added to the mixture and incubated for
2.5 h at room temperature. 6.6 nM anti-His6-XL665 and 0.45 nM anti-FLAG-EuCryptate antibodies
(Cisbio, Inc., Bedford, MA, USA) were then added to the reaction and incubated at room temperature
for 3 h. The HTRF signal was recorded using a PerkinElmer EnSpire multimode plate reader [27].
3.5. DNA Binding Experiments
DNA binding was measured using a plate-based assay following fluorescence polarization of
a fluorescent 21-mer duplex DNA substrate (21T/21B duplex oligonucleotide) with an AlexaFluor
488 modification at the 5′-end of the 21T oligonucleotide. Peptide or DMSO (control, without peptide)
were incubated at room temperature for 5 min in the IN-activity buffer in the absence or the presence
of IN (400 nM). After addition of the DNA (10 nM), fluorescence anisotropy was measured every 30 s
for 30 min using an Envision plate reader (Perkin Elmer, Waltham, MA, USA).
3.6. Crosslinking Experiments
Peptide 15 (111 µM), containing a photo-reactive Bpa group and a biotin linked to its amino
terminus, was incubated for 2 h at 37 ◦C in the absence or the presence of IN (3.2 µM) before UV
irradiation (5 min at 254 nM). After adding 2 × 10 µL of loading buffer, samples were heat-denatured
at 95 ◦C (5 min). Products were separated on 16% SDS-PAGE and transferred to a PVDF membrane
using an iBlot system (Invitrogen, Carlsbad, CA, USA). IN was revealed by Western blot using a
primary rabbit polyclonal antibody directed against the IN CTD (AIDS Reagent program, cat. No. 758)
and an anti-rabbit secondary antibody from Li-COR (680 nm), while the biotinylated peptide was
revealed using streptavidin coupled to AlexaFluor 750. Reading was performed using an Odyssey®
Infrared Imaging System (LI-COR Biotechnology, Lincoln, NE, USA).
4. Conclusions
Vpr-derived peptides have previously been shown to inhibit IN function in in vitro assays.
Identification of the sites where these peptides interact with IN could potentially facilitate the
development of a new class of IN inhibitors. Starting with the Vpr (69–75) sequence found in the
α-helix III, we developed peptide 1a, which inhibits IN in vitro at low micromolar concentrations by
a mechanism that does not appear to involve disrupting IN–DNA interactions. Furthermore, unlike
ALLINIs, peptide 1a fails to promote aberrant IN multimerization. We have further identified the
outward-facing i and i + 4 α-helix III residues Vpr73 Arg and Vpr70 Ile as being particularly important
for IN inhibitory potency, which may suggest that these residues interact with IN. Collectively,
our findings indicate that the mode of action of peptide 1a is distinct from both clinically used
INSTIs and investigational ALLINIs.
To define the interactions of Vpr-derived peptides with IN, we prepared 15 as a biotinylated
photoprobe variant of peptide 1a and demonstrated its ability to covalently bind to IN. It should be
noted that the same helix III motif of Vpr, which gives rise to the peptide IN inhibitors, is also involved
in interactions of Vpr with the human Vpr-binding protein DCAF1 [51]. This further supports the
potential of Vpr-derived biotinylated probes, such as 15, to investigate the specificity of Vpr-based IN
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inhibitors and their role and potential binding partners. Peptide 15 may facilitate studies directed at
the development of Vpr-based allosteric inhibitors.
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